12^th World Narcotic Summit

Biomarkers in Drug Design

Tech Association of British Pharmaceutical Industry, Indian Society for Clinical Organization Researcher advancements in the molecular characterization of cancers have assisted researchers to discover increasingly key molecular drivers of most cancers development. These drug discoveries have prompted a couple of novel anticancer therapeutics, and medical advantage in decided on affected character populations. Despite this, the identity of clinically applicable predictive biomarkers of response keeps to lag inside the again of. In this assessment, we speak techniques for the molecular characterization of cancers and the significance of biomarkers for the improvement of novel antitumor therapeutics.The discovery and evaluation of any novel biomarkers will preferably be specialized to Clinical Laboratory Improvement Amendments (CLIA) and Good Clinical Laboratory Practice (GCLP) standards, a good way to make certain accuracy and reproducibility of laboratory approaches. Predictive biomarkers endorse the chance of response to a specific antitumor therapy. Such assays should be scientifically sound, Predictive biomarkers consist of every tumour-unique and surrogate biomarker and are crucial to accelerating the drug improvement process.

• Regulatory Prospects in BRIC countries
• Product Similarity for Biosimilars & Analytical Challenges
• Role of Medical Affairs in Biosimilars
• Regulatory strategy for generics and Biosimilars